Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086026 | 0.89 | METTL3 (0.44) | METTL3MAOBALDH1A1L3MBTL1HTT | |
| SCHEMBL19086185 | 0.88 | METTL3 (0.43) | METTL3MAOBALDH1A1L3MBTL1HTT | |
| SCHEMBL19086190 | 0.84 | ROCK2 (0.48) | METTL3ROCK2ROCK1MAPK14 | |
| SCHEMBL19086351 | 0.83 | MAOB (0.44) | METTL3MAOBHTTSMN1; SMN2ROCK2 | |
| SCHEMBL19086995 | 0.83 | ROCK2 (0.47) | METTL3MAOBALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL19086209 | 0.83 | ROCK2 (0.43) | METTL3MAOBALDH1A1L3MBTL1HTT | |
| SCHEMBL19086223 | 0.82 | METTL3 (0.43) | METTL3MAOBALDH1A1CTNNB1WNT3A | |
| SCHEMBL19086249 | 0.82 | ROCK2 (0.50) | METTL3HTTSMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL19086259 | 0.82 | METTL3 (0.42) | METTL3MAOBHTTSMN1; SMN2ROCK2 | |
| SCHEMBL19086198 | 0.81 | HDAC6 (0.38) | METTL3MAOBALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017114275-A1 | COMPOUND FOR INHIBITING ROCK, PREPARATION METHOD AND USE OF SAME | 成都先导药物开发有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290228-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | BCL6, BCL3, BCL9 | METTL3 269/4885MAOB 1158/4885ALDH1A1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.